Biomolecular Analysis for Predicting Response to Regorafenib

Fondazione Policlinico Universitario Agostino Gemelli IRCCS53 enrolled

Overview

The study envisages NGS analysis on tumor tissue from patients treated with regorafenib for recurrent glioblastoma as per standard care, with the aim to identify predictive biomarkers for response.

Study Type

INTERVENTIONAL

Allocation

Purpose

OTHER

Masking

NONE

Enrollment

Conditions

Glioblastoma Glioblastoma, IDH-wildtype

Interventions

Biomolecular tumor analysisDIAGNOSTIC_TEST

NGS analysis, other molecular analyses on FFPE tumor tissue

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. recurrent glioblastoma after surgery and chemoradiation with temozolomide; 2. indication to treatment with regorafenib per standard of care; 3. written informed consent. Exclusion Criteria: None.

Locations (1)

Fondazione Policlinico Universitario A. Gemelli IRCCS

Rome, Italy

Outcomes

Primary Outcomes

Overall survival

Interval between tumor diagnosis and death or end of follow-up

Time frame: through study completion, an average of 3 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.